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Abstract: Intestinal dysbiosis has been described in patients with certain gastrointestinal conditions
including irritable bowel syndrome (IBS) and ulcerative colitis. 2′-fucosyllactose (2′-FL), a prebiotic
human milk oligosaccharide, is considered bifidogenic and butyrogenic. To assess prebiotic effects of
2′-FL, alone or in combination with probiotic strains (potential synbiotics), in vitro experiments were
conducted on stool from healthy, IBS, and ulcerative colitis adult donors. In anaerobic batch culture
fermenters, Bifidobacterium and Eubacterium rectale-Clostridium coccoides counts, and short-chain fatty
acids (SCFAs) including butyrate increased during fermentation with 2′-FL and some of the 2′-
FL/probiotic combinations. In a subsequent open-label pilot trial, the effect of a 2′-FL-containing
nutritional formula was evaluated in twelve adults with IBS or ulcerative colitis. Gastrointestinal
Quality of Life Index (GIQLI) total and gastrointestinal symptoms domain scores, stool counts of
Bifidobacterium and Faecalibacterium prausnitzii, and stool SCFAs including butyrate, increased after six
weeks of intervention. Consistent with documented effects of 2′-FL, the batch culture fermentation
experiments demonstrated bifidogenic and butyrogenic effects of 2′-FL during fermentation with
human stool samples. Consumption of the 2′-FL-containing nutritional formula by adults with IBS
or ulcerative colitis was associated with improvements in intra- and extra-intestinal symptoms, and
bifidogenic and butyrogenic effects.
Keywords: 2′-FL; dysbiosis; fucosyllactose; gut microbiota; human milk oligosaccharides; irritable
bowel syndrome; inflammatory bowel disease; prebiotics; probiotics
1. Introduction
Irritable bowel syndrome (IBS) [1], inflammatory bowel disease (IBD) [2], and celiac
disease [3] are chronic gastrointestinal conditions with predominantly differing patho-
genesis. Interestingly, these conditions are characterized by at least some level of chronic
intestinal mucosal inflammation [4–6]. However, in contrast to patients with IBD and celiac
disease, the intestinal inflammation in patients with IBS is considered low grade [4,5].
Pathophysiology shared among individuals with IBS, IBD, and celiac disease includes
dysbiosis, defined as “any change to the composition of resident commensal communi-
ties relative to the community found in healthy individuals” [7]. Patients with IBS [8,9],
IBD [10,11], and celiac disease [12] may have reduced stool counts of the genus Bifidobac-
terium and the butyrate-producing species Faecalibacterium prausnitzii.
According to recent consensus statements by the International Scientific Association
for Probiotics and Prebiotics (ISAPP), a prebiotic is defined as “a substrate that is selectively
utilized by host microorganisms conferring a health benefit” [13], probiotics are defined as
“live microorganisms that, when administered in adequate amounts, confer a health benefit
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on the host” [14], and a synbiotic is defined as “a mixture comprising live microorganisms
and substrate(s) selectively utilized by host microorganisms that confers a health benefit
on the host” [15]. Prebiotics and probiotics represent non-pharmacologic approaches
for addressing dysbiosis associated with IBS [16–18], IBD [19,20], and celiac disease [21].
Prebiotics support the growth and activity of specific health-promoting, non-pathogenic
microorganisms such as Bifidobacterium [13]. Probiotic mechanisms among a diversity
of strains include normalization of perturbed microbiota, regulation of intestinal transit,
and short-chain fatty acid (SCFA) production [14]. SCFAs are the main end products of
anaerobic microbial fermentation in the mammalian colon [22,23]. Rapidly absorbed by the
intestinal epithelium, the pleiotropic SCFA butyrate modulates visceral sensitivity [24] and
intestinal motility [24], and regulates intestinal inflammation through multiple mechanisms
including inhibition of nuclear factor-kappa B (NFkB) activation [24,25].
Dietary prebiotics can stimulate endogenous intestinal bacteria, having the effect of
promoting butyrate production [22,26,27]. Due to abilities to increase the activity and
growth of bifidobacteria and butyrate-producers via cross-feeding mechanisms, specific
prebiotics have been described as having both bifidogenic and butyrogenic effects [26,28,29].
2′-fucosyllactose (2′-FL) is a trisaccharide prebiotic and is the human milk oligosaccharide
(HMO) most abundantly produced by the majority of nursing mothers [30]. However,
whether or not a nursing mother produces 2′-FL depends on whether or not they are
secretors of the fucosyltransferase 2 (FUT2) gene [31]. Serving as growth substrates for
intestinal bacteria in the distal colon, HMOs act as the first prebiotics consumed by nursing
infants [32–35]. In the human gastrointestinal tract, Bifidobacterium species are the main
utilizers of HMOs, which are metabolized to the SCFA acetate and lactic acid [35,36].
Health benefits to infants are apparent for HMOs [37,38] including for supplemen-
tation of 2′-FL given to formula-fed infants [39,40]. Supplemental 2′-FL and lactose-N-
neotetraose, synthesized and structurally similar to that found in human milk, has been
associated with a bifidogenic effect in infants [40]. However, data on potential benefits of
supplemental 2′-FL in adult populations are extremely limited. Elison et al. [41] reported
that oral supplementation with 2′-FL resulted in increased stool counts of Bifidobacterium in
healthy adults and Iribarren et al. [42] recently reported that a combination of 2′-FL and
lactose-N-neotetraose resulted in increased stool counts of Bifidobacterium.
Given that patients with specific chronic gastrointestinal conditions exhibit dysbiosis
(including reduced Bifidobacterium) and 2′-FL may induce bifidogenic effects, anaerobic
batch culture experiments were implemented to assess prebiotic effects of 2′-FL. Alone or
in combination with different probiotic strains (potential synbiotics), impact of 2′-FL on
the composition and metabolic activity of stool microbiota from healthy adult volunteers
and individuals with IBS or ulcerative colitis was evaluated. Several strain-identified,
commercially-available probiotic species selected from the most commonly used and
clinically-recommended bacterial genera of probiotics, Lactobacillus and Bifidobacterium [43],
were tested. A subsequent pilot trial was conducted to examine the impact of a 2′-FL-
containing nutritional formula on gastrointestinal quality of life, stool counts of commensal
microbiota, and stool SCFA concentrations in adults with IBS, IBD and celiac disease.
2. Materials and Methods
2.1. In Vitro Experiments
2.1.1. 2′-FL and Probiotic Strains
Five potential synbiotic combinations were tested as described in Table 1. The 2′-FL
and probiotic strains were supplied by Metagenics, Inc. (Aliso Viejo, CA, USA). Probiotic
suspensions were prepared for addition to fermenter vessels by centrifuging at 14,000× g
for 5 min. The supernatant was removed and cells were washed twice in anaerobic
phosphate buffer (1 M, pH 7.4). Cells were re-suspended in 1 mL phosphate buffer at a
concentration of 107 CFU/mL immediately before addition to fermenter vessels.
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Table 1. Potential Synbiotic Combinations Evaluated In Vitro.
Synbiotic 1 (S1) 2
′-FL + Lactobacillus acidophilus NCFM (ATCC 5221) +
Bifidobacterium animalis subsp. lactis Bi-07 (ATCC 5220)
Synbiotic 2 (S2)
2′-FL + L. acidophilus NCFM + B. animalis subsp. lactis Bi-07 +
Bifidobacterium animalis subsp. lactis Bl-04 (ATCC 5219) +
Lactobacillus paracasei Lpc-37 (ATCC 5275)
Synbiotic 3 (S3) 2
′-FL + L. acidophilus NCFM + B. animalis subsp. lactis Bi-07
+ Lactobacillus rhamnosus GG (ATCC 7017)
Synbiotic 4 (S4) 2′-FL + L. rhamnosus GG
Synbiotic 5 (S5) 2′-FL + Lactobacillus salivarius UCC118
2.1.2. Batch Cultures
Anaerobic batch culture experiments were used to investigate the ability of stool
microbiota to utilize 2′-FL and to test different potential synbiotic combinations containing
2′-FL. These were performed in three populations in triplicate using stool samples from
9 different volunteers (healthy, n = 3; IBS, n = 3; ulcerative colitis, n = 3). Donors were aged
between 24 and 40 years old, who had not received antibiotics, or prebiotic or probiotics
supplements for at least six months prior to sample collection. IBS donors had received
a medical diagnosis and were not under any treatment at the time of the experiment.
Ulcerative colitis donors were being treated with mesalazine, and all were in remission at
the time of this study. Sterile gently stirred pH-controlled batch culture 10 mL fermentation
vessels were aseptically filled with 9 mL of sterile (autoclaved) basal nutrient medium
and sparged with O2-free N2 (15 mL/min) overnight to establish anaerobic conditions.
The basal medium (per liter) consisted of: 2 g peptone water, 2 g yeast extract, 0.1 g NaCl,
0.04 g K2HPO4, 0.04 g KH2PO4, 0.01 g MgSO4.7H2O, 0.01 g CaCl.6H2O, 2 g NaHCO3, 2 mL
Tween 80, 0.05 g hemin, 0.01 mL vitamin K1, 0.5 g L-cysteine-HCl, 0.5 g bile salt and 4 mL
resazurin solution (0.25 g/L). 2′-FL (1% w/v) and probiotic combinations (107 CFU per
strain) were added to fermentation vessels just before the addition of the fecal slurry which
was prepared by homogenizing fresh human feces (10%, w/v) in anaerobic phosphate-
buffered saline. Vessels were kept at 37 ◦C using a circulating water bath and pH controlled
between 6.7 and 6.9 using an automated pH controller (Fermac 260, Electrolab, Tewkesbury,
UK). Each vessel was inoculated with 1 mL of fresh fecal slurry. Additionally, vessels with
fructooligosaccharides (FOS)/inulin mixture (1% w/v) and without any substrate were
used as positive and negative controls respectively. Batch culture fermentations were run
for 24 h and samples were collected at 0, 8, and 24 h.
2.1.3. Flow Cytometry-Fluorescence In Situ Hybridization for Bacterial Enumerations
Samples (750 µL) were centrifuged at 13,000× g for 5 min at room temperature.
Supernatants were collected and filtered through a 0.22 µm Millipore syringe filter for gas
chromatography analysis. Pellets were fixed for further fluorescence in situ hybridization
and kept at −20 ◦C. Briefly, after centrifugation pellets were resuspended in 375 µL of 1X
PBS and 1150 µL of cold 4% (v/v) paraformaldehyde. The suspension was mixed and
stored at 4 ◦C for 4–6 h. After incubation, samples were washed twice with 1 mL of 1X
PBS. Finally, samples were centrifuged at 13,000× g for 5 min, supernatant was discarded
and the pellet was resuspended in 300 µl of 1X PBS and 300 µL of ethanol. Samples were
vortexed and stored at −20 ◦C for further analysis.
For Flow-FISH cytometry, we used 75 µL of the fixed samples. Fixed cells were
washed twice with PBS and pre-treated for 10 min with lysozyme at 1 mg/mL. Cells were
resuspended in 1 mL hybridization buffer. All hybridizations were performed in the dark
at 35 ◦C overnight in the hybridization solution containing genus- and group-specific 16S
rRNA-targeted oligonucleotide probes. Cells were centrifuged at 10,000× g for 3 min,
resuspended in pre-warmed washing buffer and incubated at 37 ◦C for 20 min to remove
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non-specific binding of the probe. Finally, cells were centrifuged at 10,000× g for 3 min
and resuspended in PBS for flow cytometry analysis. Probes used are described in Table 2.
Table 2. 16S rRNA-Targeted Oligonucleotide Probes Used for In Vitro Experiments.
Probe Name Sequence (5′ to 3′) Targeted Bacterial Group Reference
Non Eub ACTCCTACGGGAGGCAGC Negative control Wallner et al., 1993 [44]
Eub338 GCTGCCTCCCGTAGGAGT Total bacteria Daims et al., 1999 [45]
Eub338II GCAGCCACCCGTAGGTGT Total bacteria Daims et al., 1999 [45]
Eub338III GCTGCCACCCGTAGGTGT Total bacteria Daims et al., 1999 [45]
Ato291 GGTCGGTCTCTCAACCC Atopobium cluster Harmsen et al., 2000 [46]
Bac303 CCAATGTGGGGGACCTT Bacteroides/Prevotella Manz et al., 1996 [47]
Bif164 CATCCGGCATTACCACCC Bifidobacterium spp. Langendijk et al., 1995 [48]
Chis150 TTATGCGGTATTAATCTYCCTTT Clostridium histolyticum (Clostridium cluster I and II) Franks et al., 1998 [49]
Prop853 ATTGCGTTAACTCCGGCAC Clostridium cluster IX Walker et al., 2005 [50]
DSV687 TACGGATTTCACTCCT Desulfovibrio spp. Hold et al., 2003 [51]
Erec482 GCTTCTTAGTCARGTACCG Eubacterium rectale/Clostridium coccoides(Clostridium cluster IVXa and IVXb) Franks et al., 1998 [49]
Fprau655 CGCCTACCTCTGCACTAC Faecalibacterium prausnitzii Devereux et al., 1992 [52]
Lab158 GGTATTAGCAYCTGTTTCCA Lactobacillus/Enterococcus Harmsen et al., 1999 [53]
Rrec584 TCAGACTTGCCGYACCGC Roseburia spp. Walker et al., 2005 [50]
2.1.4. In Vitro SCFA Analysis
Samples from each fermentation time were centrifuged at 13,000× g for 10 min to obtain
the supernatants which were kept at −20 ◦C until analysis. Before analysis, samples were
extracted and derivatised following the method described by Ferreira-Lazarte et al. [54]. A
5890 Series II Gas Chromatograph (Hewlett Packard) fitted with a Rtx-1 10 m × 0.18 mm
column with a 0.20µm coating (Crossbond 100% dimethyl polysiloxane; Restek) was used
for analysis. Helium was used as the carrier gas at a flow rate of 0.7 mL/min. Injector and
detector temperatures were 275 ◦C. Oven temperature was programmed from 63 ◦C for
3 min and then heated to 190 ◦C at a heating rate of 3 ◦C/min and held at 190 ◦C for 3 min.
SCFA standards analysis was also carried out to quantify concentrations of all compounds.
2.1.5. Statistical Analysis of In Vitro Data
Statistical analyses were performed using Graph Pad Prism 8 (Graph Pad Software
Inc., San Diego, CA, USA). One-way ANOVA with Dunnet’s multiple comparison test
was used to determine significant differences from baseline within the same substrate.
Differences were considered to be significant when p < 0.05.
2.2. Pilot Clinical Trial
2.2.1. Clinical Trial Design
To evaluate potential effects of a 2′-FL-containing nutritional formula, a single-arm,
open-label, pilot trial was implemented. The clinical trial protocol was approved by Quo-
rum Review Board (Seattle, WA, USA) and registered at ClincalTrials.gov (NCT03011593).
Participants provided written informed consent prior to participation in this study.
The interventional period included two clinical visits with questionnaires adminis-
tered and stool samples collected at baseline and at the study end point (after six weeks).
The Gastrointestinal Quality of Life Index (GIQLI) [55], administered to all participants, was
the primary outcome measure. Secondary outcome measures were the Digestive Symptom
Frequency Questionnaire (DSFQ) [56] and the Inflammatory Bowel Disease Questionnaire
(IBDQ) [57], administered only to participants with IBS and IBD, respectively. Exploratory
outcome measures were stool CFU counts of commensal bacteria and stool SCFA levels.
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2.2.2. Clinical Trial Participants and Recruitment
Up to twenty adults aged 21–75 years, with a body mass index (BMI) of 19–40 kg/m2,
and with previously diagnosed IBS, ulcerative colitis, Crohn’s disease or celiac disease
were recruited at four medical clinics in the United States (located in La Jolla, CA; Forney,
TX; Avon, CT; and South Orange, NJ). Potential participants were approached by clinicians
associated with this study. Target enrollment was up to twenty individuals. Exclusion
criteria were as follows: taking oral or intravenous antibiotic, antiparasitic, or antifungal
medications; gastrointestinal surgery within three months prior to screening; currently
having a colostomy or ileostomy bag in place; cancer within the last five years; or women
who were lactating, pregnant or planning pregnancy during the study period. Furthermore,
participants were excluded if they had done any of the following within 28 days prior to
screening: initiated or made changes to medications or supplements, initiated or made
changes to an exercise regimen or food plan, participated in a significant diet or weight loss
program, used recreational drugs/substances, or participated in another research study.
Unless medically indicated, participants were asked to refrain from making changes to their
medications or supplements, exercise routine or diet for the duration of their participation
in this study.
2.2.3. Clinical Trial Intervention
The studied nutritional formula was manufactured and supplied by Metagenics, Inc.
(Aliso Viejo, CA, USA) in fourteen-serving containers. The nutritional formula contained
two grams per serving of 2′-FL plus micronutrients (vitamins A, B6, B12, C, D3, and E, biotin,
calcium, chromium, copper, folate, iodine, iron, magnesium, manganese, pantothenic acid,
phosphorus, riboflavin, selenium, thiamin, and zinc), macronutrients (protein, carbohy-
drates, fat, and fiber), amino acids, and isomalto-oligosaccharide. Participants were asked
to add two scoops of the nutritional formula (40 g) to chilled water or juice (8–10 ounces)
and drink it as a reconstituted beverage for six weeks. Participants consumed the beverage
twice per day and therefore were administered four grams 2′-FL per day.
2.2.4. Quality of Life Assessment and Stool Sample Analysis
The GIQLI, DSFQ, and IBDQ were scored as previously described [55–57]. Stool
samples were shipped to Genova Diagnostics (Asheville, NC, USA) within twenty-four
hours of collection; commensal gut microbiota were identified using 16S ribosomal RNA
gene PCR and concentrations of SCFA were measured using gas chromatography–mass
spectrometry (GC-MS) as previously described [58].
2.2.5. Statistical Analysis of Clinical Trial Data
Given that the clinical trial was a pilot trial with data collected at only two time points,
statistical analyses were limited to data from participants who completed the trial. Study
measures are presented as the mean and standard deviation (SD) at each time point. For
questionnaire and SCFA data, changes from baseline to study completion were analyzed
using paired t-tests to identify significant differences. Microbiota PCR data were log
transformed prior to calculation of geometric mean percent change and analyzed using
paired t-tests. Statistically-significant (p < 0.05) microbiota parameters were subsequently
evaluated using a Wilcoxon signed rank analysis, a more conservative test, to confirm
statistical significance. In the case of microbiota PCR data that were outside of laboratory
detection limits, the extreme detectable value was imputed for analysis. Given the small
sample size of this study, effect size as Cohen’s d was calculated between baseline and the
study end point for all continuous measures. Cohen’s d was calculated as (week 6 mean–
baseline mean)/(baseline standard deviation) and interpreted as small (d = 0.20), medium
(d = 0.50), or large (d = 0.80) effect size. Statistical analyses were performed using R (The R
Foundation for Statistical Computing, software version 3.6.0, Vienna, Austria).
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3. Results
3.1. In Vitro Study
3.1.1. Effect of Fermentation on Bacterial Populations
Bacterial counts obtained by Flow-FISH are shown in Supplementary Figure S1
(Figure S1). The most noticeable change in the microbiota composition along the fer-
mentations of stool samples from all groups was a significant increase in Bifidobacterium at
8 and 24 h of fermentation with the positive control, the 2′-FL, and several 2′-FL/probiotic
combinations compared to baseline (Figure 1). Although the observed bifidogenic effect
was significant overall, the increment was smaller with IBS donors due to higher inter-
individual variation in the IBS donors. Closer examination, donor by donor in the IBS
group, showed that this variation was due a low bifidogenic response (0.5 log) to 2′-FL
and 2′-FL/probiotic combinations in one of the three IBS donors. However, the bifidogenic
effect observed in the two additional IBS donors was similar to fermentations with healthy
and ulcerative colitis donors. In addition, abundance of Eubacterium rectale-Clostridium
coccoides (butyrate producers) was also significantly higher in presence of 2′-FL and 2′-
FL/probiotic combinations after 8 h of fermentation (Figure 1). Roseburia species, another
butyrate producer, also displayed a significant increment at 8 h in response of FOS/inulin
mixture and 2′-FL in healthy and IBS fermentations but not in ulcerative colitis fermenta-
tions (Supplementary Figure S1). Interestingly, unlike healthy donors, stool microbiota of
IBS and ulcerative colitis donors displayed a significant increase in Atopobium in response to
2′-FL and potential synbiotic treatments (Figure 1). Overall, no discernible differences were
observed when 2′-FL/probiotic combinations were compared to 2′-FL alone (Figure 1).




Figure 1. Bifidobacterium, Clostridium coccoides/Eubacterium rectale and Atopobium cluster populations at 0, 8, and 24 h of 
fermentation with no substrate/negative control (NC); positive control (FOS/inulin mixture); 2′-FL; S1: 2′-FL + L. acidophilus 
NCFM + B. lactis Bi-07; S2: 2′-FL+ L. acidophilus NCFM + B. lactis Bi-07 + B. lactis Bl-04 + L. paracasei Lpc-37; S3: 2′-FL + L. 
acidophilus NCFM + B. lactis Bi-07 + L. rhamnosus GG; S4: 2′-FL + L. rhamnosus GG; S5: 2′-FL + L. salivarius UCC118. Error 
bars show SEM (n = 3). Significant differences from baseline (time 0) are denoted with * (p ≤ 0.05) or ** (p ≤ 0.01). 
3.1.2. Effect of Fermentation on Short-Chain Fatty Acid (SCFA) Production 
Acetate was the main SCFA detected during the fermentation of all prebiotics and 
potential synbiotics tested and its production accounted for approximately 75% of total 
SCFAs. Significant increments of acetate and propionate (the second most prevalent 
SCFA) were observed at the end of fermentation for all substrates and the three donor 
groups (Figure 2). Moderate increments of butyrate were also observed after 24 h. Alt-
hough this increment was only significant for FOS and one 2′-FL/probiotic combination 
in fermentations with stool microbiota of healthy donors, significant increases in butyrate 
with 2’-FL and 2′-FL/probiotic combinations were detected in ulcerative colitis donor fer-
mentations and also with FOS and some 2′-FL/probiotic combinations in IBS donor fer-
mentations (Figure 2). 
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Figure 1. Bifidobacterium, Clostridium coccoides/Eubacterium rectale and Atopobium cluster populations at 0, 8, and 24 h of
fermentation with no substrate/negative control (NC); positive control (FOS/inulin mixture); 2′-FL; S1: 2′-FL + L. acidophilus
NCFM + B. lactis Bi-07; S2: 2′-FL+ L. acidophilus NCFM + B. lactis Bi-07 + B. lactis Bl-04 + L. paracasei Lpc-37; S3: 2′-FL + L.
acidophilus NCFM + B. lactis Bi-07 + L. rham osus GG; S4: 2′-FL + L. rhamnosus GG; S5: 2′-FL + L. salivarius UCC118. Error
bars show SEM (n = 3). Significant differences from baseline (time 0) are denoted with * (p ≤ 0.05) or ** (p ≤ 0.01).
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3.1.2. Effect of Fermentation on Short-Chain Fatty Acid (SCFA) Production
Acetate was the main SCFA detected during the fermentation of all prebiotics and
potential synbiotics tested and its production accounted for approximately 75% of total
SCFAs. Significant increments of acetate and propionate (the second most prevalent SCFA)
were observed at the end of fermentation for all substrates and the three donor groups
(Figure 2). Moderate increments of butyrate were also observed after 24 h. Although this
increment was only significant for FOS and one 2′-FL/probiotic combination in fermenta-
tions with stool microbiota of healthy donors, significant increases in butyrate with 2′-FL
and 2′-FL/probiotic combinations were detected in ulcerative colitis donor fermentations
and also with FOS and some 2′-FL/probiotic combinations in IBS donor fermentations
(Figure 2).




Figure 2. Acetate, propionate and butyrate concentration at 0, 8, and 24 h of fermentation with no substrate/negative 
control (NC); positive control (FOS/inulin mixture); 2′-FL; S1: 2′-FL + L. acidophilus NCFM + B. lactis Bi-07; S2: 2′-FL + L. 
acidophilus NCFM + B. lactis Bi-07 + B. lactis Bl-04 + L. paracasei Lpc-37; S3: 2′-FL + L. acidophilus NCFM + B. lactis Bi07 + L. 
rhamnosus GG; S4: 2′-FL + L. rhamnosus GG; S5: 2′-FL + L. salivarius UCC118. Error bars show SEM (n = 3). Significant 
differences from baseline (time 0) are denoted with * (p ≤ 0.05) or ** (p ≤ 0.01). 
3.2. Pilot Clinical Trial 
3.2.1. Participant Characteristics 
Twenty participants enrolled in this study and twelve completed it. Demographic 
parameters of the twelve participants who completed this study are presented in Table 3. 
The mean BMI of these twelve individuals was 23.8 kg/m2 (with a range from 19.4 to 29.6 
kg/m2). The eight individuals who did not complete this study included two that dropped 
out/declined to participate before beginning the study intervention, three that dropped 
out due to non-serious adverse events, and three who were lost to follow up. The partici-
pants who dropped out due to adverse events reported worsening of pre-existing gastro-
intestinal symptoms, gastrointestinal upset, and a non-study-related viral infection. Data 









































































































































































































Figure 2. Acetate, propionate and butyrate concentration at 0, 8, and 24 h of fermentation with no substrate/negative control
(NC); positive control (FOS/inulin mixture); 2′-FL; S1: 2′-FL + L. acidophilus NCFM + B. lactis Bi-07; S2: 2′-FL + L. acidophilus
NCFM + B. lactis Bi-07 + B. lactis Bl-04 + L. paracasei Lpc-37; S3: 2′-FL + L. acidophilus NCFM + B. lactis Bi07 + L. rhamnosus
GG; S4: 2′-FL + L. rhamnosus GG; S5: 2′-FL + L. salivarius UCC118. Error bars show SEM (n = 3). Significant differences from
baseline (time 0) are denoted with * (p ≤ 0.05) or ** (p ≤ 0.01).
3.2. Pilot Clinical Trial
3.2.1. Participant Characteristics
Twenty participants enrolled in this study and twelve completed it. Demographic
parameters of the twelve participants who completed this study are presented in Table 3.
The mean BMI of these twelve individuals was 23.8 kg/m2 (with a range from 19.4 to
29.6 kg/m2). The eight individuals who did not complete this study included two that
dropped out/declined to participate before beginning the study intervention, three that
dropped out due to non-serious adverse events, and three who were lost to follow up. The
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participants who dropped out due to adverse events reported worsening of pre-existing
gastrointestinal symptoms, gastrointestinal upset, and a non-study-related viral infection.
Data from the twelve participants that completed this study were analyzed.
Table 3. Pilot Trial Participant Demographics.
Mean ± SD or n (%)




Body Mass Index (kg/m2) 23.8 ± 3.4
Race (Ethnicity)
White (not Hispanic/Latino) 8 (66.7%)
White/Native American (not Hispanic/Latino) 2 (16.7%)
White (Hispanic/Latino) 1 (8.3%)
Black (not Hispanic/Latino) 1 (8.3%)
Gastrointestinal Condition
Irritable bowel syndrome (IBS) 7 (58.3%)
Ulcerative colitis (UC) 4 (33.3%)
Celiac disease 1 (8.3%)
Abbreviations: kg/m2, kilograms per square meter; SD, standard deviation.
3.2.2. Impact on Gastrointestinal Quality of Life
Compared to baseline, some gastrointestinal quality of life questionnaire scores im-
proved after six weeks (Table 4). Gastrointestinal Quality of Life Index (GIQLI) (ad-
ministered to all participants) total score and “gastrointestinal symptoms” domain score
increased (p < 0.05) with a medium effect size (d = 0.59 and d = 0.79, respectively). GIQLI
“Social function” domain score increased (p < 0.01) with a small effect size (d = 0.42). Inflam-
matory Bowel Disease Questionnaire (IBDQ) (administered only to participants with IBD)
domain score increased (p < 0.001) compared to baseline, with a large effect size (d = 1.65).
Digestive Symptom Frequency Questionnaire (DSFQ) (administered only to participants
with IBS) score did not change.
Table 4. Pilot Trial Gastrointestinal Quality of Life Questionnaire Score Changes Over 6 Weeks.
Score
Range




p 1 Cohen’s D
Mean SD Mean SD
GIQLI Total Score 0–144 94.3 25.5 109.4 19.2 15.1 20.8% 0.020 0.59
GIQLI-Gastrointestinal Symptoms 0–76 53.3 10.3 61.4 7.7 8.1 18.1% 0.022 0.79
GIQLI-Physical Function 0–28 15.6 7.4 17.8 6.1 2.2 36.5% 0.164 0.30
GIQLI-Social Function 0–16 10.7 3.8 12.3 3.7 1.6 18.4% 0.004 0.42
GIQLI-Emotional Function 0–20 12.0 5.8 14.7 4.5 2.7 46.5% 0.139 0.47
IBDQ Total Score 32–224 134.0 52.4 179.0 36.1 45.0 43.6% 0.078 0.86
IBDQ-Bowel Symptoms 10–70 43.0 19.4 56.3 11.7 13.3 44.3% 0.165 0.69
IBDQ-Systemic Systems 5–35 16.8 6.2 27.0 6.3 10.2 66.9% 0.000 1.65
IBDQ-Social Function 5–35 22.0 9.9 27.8 7.5 5.8 41.5% 0.239 0.59
IBDQ-Emotion Health 12–84 51.5 18.7 68.0 11.7 16.5 43.3% 0.098 0.88
DSFQ Total Score 0–16 9.0 3.8 8.4 5.0 −0.6 −10.3% 0.522 −0.16
1 p-values calculated using paired t-tests. Abbreviations: ∆, change; DSFQ, Digestive Symptom Frequency Questionnaire; GIQLI,
Gastrointestinal Quality of Life Index; IBDQ, Inflammatory Bowel Disease Questionnaire; SD, standard deviation.
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3.2.3. Impact on Stool Bacteria Counts
In the clinical trial, counts of the majority of analyzed stool bacteria did not change af-
ter consuming the 2′-FL-containing nutritional formula for six weeks (Table 5). However, in-
creases were observed in the following: Bifidobacterium species, Bifidobacterium longum, Fae-
calibacterium prausnitzii, Anaerotruncus colihominis, and Pseudoflavonifractor species (p < 0.05)
with medium or greater effect sizes (d > 0.5).
Table 5. Pilot Trial Stool Bacteria Count Changes Over 6 Weeks.
Phylum Microbiota(CFU/g Stool)
Log Transformed Data
Baseline Week 6 Geometric
Mean % ∆
p 1 Cohen’s D
Mean SD Mean SD
Actinobacteria
Bifidobacterium spp. 20.1 1.6 21.6 1.7 356.3% * 0.026 0.95
Bifidobacterium longum 17.4 2.0 19.4 1.6 650.0% * 0.003 0.99
Collinsella aerofaciens 17.6 3.0 18.1 3.5 65.7% 0.392 0.17
Bacteroidetes
Bacteroides-Prevotella group 20.2 0.9 21.2 1.3 169.0% 0.101 1.09
Bacteroides vulgatus 19.8 2.5 20.9 2.6 190.4% 0.081 0.43
Barnesiella spp. 16.0 2.0 15.4 2.9 −46.1% 0.468 −0.31
Odoribacter spp. 15.6 2.5 14.8 3.6 −54.9% 0.369 −0.32
Prevotella spp. 14.1 2.0 14.9 1.8 116.2% 0.301 0.39
Euryarchaeota Methanobrevibacter smithii 13.1 2.0 14.0 2.1 134.7% 0.290 0.42
Firmicutes
Anaerotruncus colihominis 14.5 1.6 16.1 1.1 402.6% * 0.018 1.00
Butyrivibrio crossotus 9.9 1.5 10.7 3.1 111.7% 0.422 0.51
Clostridium spp. 21.0 1.6 21.9 1.9 156.9% 0.125 0.58
Coprococcus eutactus 14.1 2.3 14.1 2.7 −2.4% 0.983 −0.01
Faecalibacterium prausnitzii 20.6 2.2 22.1 1.8 353.7% * 0.029 0.67
Lactobacillus spp. 19.5 2.5 20.5 2.4 160.7% 0.252 0.39
Pseudoflavonifractor spp. 18.0 1.5 19.2 1.2 226.4% * 0.016 0.80
Roseburia spp. 20.7 1.8 21.9 1.5 252.8% 0.062 0.68
Ruminococcus spp. 17.7 2.0 18.4 2.1 97.5% 0.273 0.34
Veillonella spp. 16.1 3.0 16.9 1.7 118.8% 0.331 0.26
Fusobacteria Fusobacterium spp. 9.6 2.3 10.6 2.0 171.8% 0.111 0.44
Proteobacteria
Desulfovibrio piger 10.3 2.1 10.5 2.0 12.2% 0.877 0.06
Escherichia coli 16.5 3.0 17.0 1.7 67.9% 0.607 0.17
Oxalobacter formigenes 14.1 1.7 13.9 2.5 −16.9% 0.833 −0.11
Verrucomicrobia Akkermansia muciniphila 12.6 2.0 12.9 2.0 33.6% 0.702 0.15
1 p-values calculated using paired t-tests. * p-values confirmed with a Wilcoxon signed rank test (p < 0.05). Abbreviations: ∆, change; CFU,
colony-forming unit; g, gram; SD, standard deviation; spp., species.
3.2.4. Impact on Stool Short-Chain Fatty Acids (SCFAs)
After six weeks, butyrate, acetate, and total stool SCFAs increased (p < 0.05) with large
effect sizes (d ≥ 0.80) (Table 6).
Table 6. Pilot Trial Stool Short-Chain Fatty Acids (SCFAs) Over 6 Weeks.
SCFA
(Micromol/g Stool)
Baseline Week 6 Mean
% ∆
p 1 Cohen’s D
Mean SD Mean SD
Total SCFA 46.30 13.30 76.43 37.04 72.2% 0.026 2.27
Butyrate 8.12 4.76 16.71 9.63 594.0% 0.040 1.80
Acetate 28.24 7.28 45.65 23.90 64.3% 0.035 2.39
Propionate 10.03 4.71 14.06 8.39 42.4% 0.074 0.85
1 p-values calculated using paired t-tests. Abbreviations: ∆, change; g, gram.
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4. Discussion
In the batch culture fermentation model, 2′-FL demonstrated prebiotic effects with
increases in Bifidobacterium and SCFAs as well as substantial increments in other beneficial
groups of the microbiota as Clostridium cluster XIVa and Roseburia spp. (butyrate producers).
A previous in vitro study has also shown the ability of Bifidobacterium and Eubacterium to
utilize fucosyllactose [29].
During fermentation, 2′-FL showed a bifidogenic effect similar to the positive control
FOS/inulin mixture. The impact of 2′-FL on Bifidobacterium after 24 h was similar in the
microbiota of all donors except for one individual with IBS. In the case of stool from this
volunteer, no bifidogenic effect was detected with the positive control either, although
Roseburia spp. increased with the treatments. Interestingly, this donor showed a two-fold
abundance of Roseburia spp. over Bifidobacterium at baseline. This numerical superiority
possibly provided an important competitive advantage for substrate consumption. Overall,
Bifidobacterium and Eubacterium rectale-Clostridium coccoides were the main groups affected
by 2′-FL and 2′-FL/probiotic combinations in fermentations of samples from the three
donor groups.
Interestingly, the abundance of Atopobium cluster was also significantly increased in
the presence of prebiotics and potential synbiotic combinations in individuals with IBS and
ulcerative colitis. Slight, non-significant, increments were detected in this bacterial group
in healthy donors. The role of Atopobium cluster in the human colon is not clear. However,
they are commonly isolated from healthy human stool and are typically present at 1.5–3%
of the total stool population. Atopobium cluster comprises most Coriobacteriaceae species,
including the Coriobacterium group [47].
Using the Simulator of the Human Intestinal Microbial Ecosystem (SHIME®), Šuligoj et al. [59]
recently reported that fermentation of 2′-FL resulted in a simultaneous increase in Bifidobac-
terium and SCFAs including butyrate in particular. In our in vitro experiments, fermentation
of stool samples with 2′-FL also resulted in a simultaneous increase in Bifidobacterium and
SCFAs including butyrate. As expected, the highest contribution to the SCFA increase
was due to the production of acetate probably through the growth of Bifidobacterium spp.,
but significant increments of propionate and butyrate also occurred. Overall, levels of
acetate, propionate and butyrate in the presence of 2′-FL were similar in the three stool
donor groups after 24 h fermentation, indicating that 2′-FL could be applicable for both IBS
and IBD. No major differences were observed between 2′-FL alone and the 2′-FL/probiotic
combinations on the stool microbiota composition after 24 h of fermentation and some
of the differences detected could be related to baseline variations. Because no additional
effects were seen with the addition of the probiotic strains, we concluded that combining
any of the tested probiotic strains with 2′-FL might not confer additional benefit to the host
upon translation of the in vitro findings into human subjects. Hence we proceeded with
including 2′-FL without probiotics in the nutritional formula tested in the pilot trial.
In the clinical trial, measures of gastrointestinal quality of life improved in adults
with chronic gastrointestinal conditions after a six-week course of the 2′-FL-containing
nutritional formula. Most notably, GIQLI total score and specifically the gastrointestinal
symptom domain score improved significantly over the course of the trial. The increase
in GIQLI total score (15.1 units) over six weeks exceeded what has been reported as the
minimal clinically important difference (MCID) for the GIQLI (6.42 to 7.64 units) [60].
Improving gastrointestinal quality of life is meaningful given the negative impact of IBS,
IBD, and celiac disease on health-related quality of life [61–63].
Over the course of the trial, stool microbiota counts increased at the genus and species
levels. Consistent with our in vitro fermentations and other in vitro studies [35,64–67],
the genus Bifidobacterium increased as expected. The increase in stool counts of Bifidobac-
terium, after consuming four grams 2′-FL per day for six weeks, is also in alignment with
results demonstrating that two weeks of supplementation with ten grams per day of
2′-FL [41] or four weeks of supplementation with a ten gram mixture of 2′-FL and lacto-N-
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neotetraose [42] increased stool abundance of the genus Bifidobacterium in healthy adults
and adults with IBS, respectively.
At the species level, Bifidobacterium longum also increased over time. This finding was
also anticipated, because B. longum strains produce enzymes and transporters that function
in the metabolism of HMOs and several in vitro studies have demonstrated that specific
strains of B. longum are able to consume 2′-FL in culture [33,64–67]. This finding was also
consistent with those of Elison et al. [36] showing that the increase in sequence abundance
of operational taxonomic units (OTUs) showing high sequence similarity to B. longum were
among the species of bifidobacteria most affected by 2′-FL consumption in human subjects.
Stool counts of Faecalibacterium prausnitzii, Anaerotruncus colihominis, and Pseudoflavonifrac-
tor species also increased significantly over the course of the trial. The increase in F. praus-
nitzii is particularly noteworthy because multiple studies have found that stool levels of F.
prausnitzii, which comprises about 5% of total stool microbiota in healthy individuals, are
significantly lower in patients with IBS, IBD, and celiac disease [9,68–72]. Due to the associ-
ation between low abundance of F. prausnitzii and inflammatory and metabolic diseases, F.
prausnitzii has been described as a potential bioindicator of health [73,74]. Furthermore, F.
prausnitzii has been described as a potential keystone species [75,76] signifying that it may
be critical for maintaining the organization and diversity of the gut ecosystem through
biotic interactions with other species [77]. Although changes in F. prausnitzii were not noted
in our in vitro experiments, an increase in Eubacterium rectale/Clostridium coocoides, other
main butyrate producer group, was detected. Interestingly, Cheng et al. [78] recently re-
ported that when B. longum subsp. infantis and F. prausnitzii are co-cultured in the presence
of 2′-FL, these bacteria grow faster in co-culture than in monocultures in the presence of
2′-FL. The in vitro results reported by Cheng et al. [78] are in alignment with our observed
simultaneous increase in the species B. longum and the butyrate producer F. prausnitzii
in human subjects. Furthermore, our previous work and that of other groups have also
demonstrated that prebiotics can simultaneously increase stool counts of Bifidobacterium
and F. prausnitzii in adult subjects [79,80].
Stool levels of butyrate, acetate, and total SCFAs also increased significantly over
the course of the clinical trial. Our in vitro experiments as well as other pre-clinical data
also support these clinical trial findings. It was reported that incubation of infant stool
samples with 2′-FL resulted in significantly increased SCFA production [81]. In several
in vitro experiments, Li et al. [82] demonstrated that incubation of crude HMOs isolated
from pooled human milk samples with stool samples isolated from piglets resulted in
SCFA production. Furthermore, Azagra-Boronat et al. [83] recently reported that oral 2′-FL
increased cecal butyrate in healthy suckling rats.
It is possible that the observed increases in SCFAs in the clinical trial, specifically
butyrate and acetate, were mechanistically related to the observed increases in commensal
bacteria. Stool levels of predominant butyrate producers have been shown to correlate
with stool SCFA levels [84]. Microbiota of the genera Faecalibacterium, Anaerotruncus, Pseud-
oflavonifractor, each express enzymes required for butyrate and acetate biosynthesis [85].
A. colihominis is also considered a major butyrate producer [86,87]. Furthermore, specific
strains of B. longum have been shown to produce abundant acetate when cultured on 2′-FL
as a growth substrate [64,65]. Potentially supporting the growth of butyrate-producing gut
microorganisms as well as intestinal production of butyrate may be clinically meaningful,
since it has been suggested that exogenous butyrate and butyrate-producing microor-
ganisms, such as F. prausnitzii, may represent novel therapeutic approaches for IBS and
IBD [13,88–92].
Strengths of the translational clinical trial design include successful collection of pilot
data in individuals with various gastrointestinal conditions and concurrent evaluation of
impact on quality of life, gut microbiota, and stool SCFAs following in vitro assessments.
Limitations of the clinical trial include a high rate of withdrawal, lack of a control group,
the small sample size, and completion of the trial by only one individual with celiac disease.
Furthermore, although participants who completed the trial were considered normal or
Nutrients 2021, 13, 938 12 of 16
overweight (but not obese), protocol eligibility criteria allowed for inclusion of a broad
BMI range; future trial protocols should limit BMI to fewer categories and/or include
sufficient sample size to allow for subgroup comparisons due to the influence BMI could
have on results. In addition, shifts in gut microbiota composition and increases in SCFA
cannot be attributed to 2′-FL solely given that the formula contained additional ingredients.
Improvements in intra- and extra-intestinal symptoms also cannot be attributed only to
2′-FL given that the formula also contained macro- and micronutrients that are supportive
to patients with malabsorption and malnutrition associated with chronic gastrointestinal
disease including IBD [93,94].
5. Conclusions
Consistent with documented effects of 2′-FL, our in vitro work demonstrated bifido-
genic and butyrogenic effects of 2′-FL during fermentation with human stool samples. With
no additional effects seen with the addition of probiotic strains, only 2′-FL was included in
the nutritional formula when the in vitro results were translated to human subjects. Con-
sumption of the 2′-FL-containing nutritional formula by adults with IBS or ulcerative colitis
was associated with improvements in intra- and extra-intestinal symptoms, and bifidogenic
and butyrogenic effects. Based on the promising yet preliminary clinical trial results, future
research should further explore relationships between potential impacts of the nutritional
formula on quality of life and gut microbiota composition and metabolism, including SCFA
production. To better isolate the impact of 2′-FL, the effect of the 2′-FL-containing formula
could be compared to 2′-FL only or the formula without the inclusion of 2′-FL. Patient
populations tested should include individuals with gastrointestinal conditions associated
with intestinal dysbiosis, including, but not limited to IBS, IBD, and celiac disease. In
addition, impact on the prevention of these conditions could be explored. Furthermore,
additional batch culture fermentation experiments could explore effects of 2′-FL during
fermentation with human stool samples from additional clinical populations, including
those with other gastrointestinal conditions. However, the present results are promising,
particularly in the context of the limited research on HMOs in adult populations with
chronic gastrointestinal conditions.
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